Bright Minds Biosciences Inc. (NASDAQ: DRUG) is a Healthcare company (Biotechnology) with a market capitalization of $202M. The Maz Rating grades it against the other companies in its sector.
Bright Minds Biosciences Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $20.51, Bright Minds Biosciences Inc. trades at 0.9x book value, with an EV/EBITDA of 0.6. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -12.6%, return on invested capital of -12.9% and a free cash flow yield of -8.8%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 121.97. Over the past 52 weeks the share price ranged from $17.40 to $123.75, with a beta of 0.09.
Bright Minds Biosciences Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of June 2026, Bright Minds Biosciences Inc. (DRUG) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 40.7% / 30% · Interest income / Revenue 286710300.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 40.7% / 33% · Receivables / Mkt Cap (36m) 0.15% / 49% · Interest income / Revenue 286710300.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 40.7% / 33.33% · Receivables / Mkt Cap (24m) 0.15% / 33.33% · Interest income / Revenue 286710300.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 98.9% / 33.33% · Receivables / Avg Assets (4Q) 0.40% / 33.33% · Interest income / Revenue 286710300.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 99.2% / 33.33% · (Cash+Recv) / Total Assets 99.5% / 33.33% · Interest income / Revenue 286710300.0% / 5% | Fail |
No. As of June 2026, Bright Minds Biosciences Inc. (DRUG) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Bright Minds Biosciences Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 286710300.0% of each dividend: Bright Minds Biosciences Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated June 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.